Our results showed that after BLM treatment, α-SMA expression increased up to 19.5-fold in the BLM+CMC group relative to the CT+CMC group, whereas it decreased 19.4 and 19.42-fold, respectively, in the BLM+T1 and BLM+T2 groups compared to the BLM+CMC group (Figure 2a,b). The gene discussed is BLM; the disease is Bloom syndrome.